MAPT and early-onset autosomal dominant Alzheimer disease: In vivo pharmacodynamic studies in Aβ-injected rats confirmed that sialic acid-functionalized nanostructured lipid carriers significantly improved cognitive performance and reduced features of Alzheimer’s disease, including Aβ, tau protein, and glycogen synthase kinase-3β levels [73].